LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial

MLA

J. Potenberg, et al. “LBA2 Impact of RNA Expression Signatures and Tumour Infiltrating Lymphocytes (TILs) for Pathological Complete Response (PCR) and Survival after 12 Week de-Escalated Neoadjuvant Pertuzumab + Trastuzumab ± Paclitaxel in the WSG-HER2+/HR- ADAPT Trial.” Annals of Oncology, vol. 32, May 2021, p. S48. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.03.215.

APA

J. Potenberg, Rachel Wuerstlein, Doris Augustin, O Gluz, C. Kolberg-Liedtke, J. Palatty, Christine Eulenburg, U. Nitz, S. Kuemmel, E-M. Grischke, D. Ulbrich-Gebauer, Friedrich Feuerhake, C. Biehl, Matthias Christgen, Michael Braun, Nadia Harbeck, Monika Graeser, H.H. Kreipe, & R Kates. (2021). LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial. Annals of Oncology, 32, S48. https://doi.org/10.1016/j.annonc.2021.03.215

Chicago

J. Potenberg, Rachel Wuerstlein, Doris Augustin, O Gluz, C. Kolberg-Liedtke, J. Palatty, Christine Eulenburg, et al. 2021. “LBA2 Impact of RNA Expression Signatures and Tumour Infiltrating Lymphocytes (TILs) for Pathological Complete Response (PCR) and Survival after 12 Week de-Escalated Neoadjuvant Pertuzumab + Trastuzumab ± Paclitaxel in the WSG-HER2+/HR- ADAPT Trial.” Annals of Oncology 32 (May): S48. doi:10.1016/j.annonc.2021.03.215.